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The replication and transcription activator (RTA) protein of Kaposi’s sarcoma (KS)-associated herpesvirus
(KSHV)/human herpesvirus 8 functions as the key regulator to induce KSHV lytic replication from latency
through activation of the lytic cascade of KSHV. Elucidation of the host factors involved in RTA-mediated
transcriptional activation is pivotal for understanding the transition between viral latency and lytic replication.
KSHV-RTA binding protein (K-RBP) was previously isolated as a cellular RTA binding protein of unknown
function. Sequence analysis showed that K-RBP contains a Kruppel-associated box (KRAB) at the N terminus
and 12 adjacent zinc finger motifs. In similarity to other KRAB-containing zinc finger proteins, K-RBP is a
transcriptional repressor. Mutational analysis revealed that the KRAB domain is responsible for the tran-
scriptional suppression activity of this protein and that the repression is histone deacetylase independent.
K-RBP was found to repress RTA-mediated transactivation and interact with TIF1 (transcription interme-
diary factor 1), a common corepressor of KRAB-containing protein, to synergize with K-RBP in repression.
Overexpression and knockdown experiment results suggest that K-RBP is a suppressor of RTA-mediated
KSHV reactivation. Our findings suggest that the KRAB-containing zinc finger protein K-RBP can suppress
RTA-mediated transactivation and KSHV lytic replication and that KSHV utilizes this protein as a regulator
to maintain a balance between latency and lytic replication.
Kaposi’s sarcoma (KS)-associated herpesvirus (KSHV), also
referred to as human herpesvirus 8, belongs to the -2 herpes-
virus family (9). KSHV can establish latent infection in in-
fected cells and can be reactivated to lytic replication (23, 62).
The KSHV replication and transcription activator (RTA), en-
coded by KSHV immediately-early gene open reading frame
50 (ORF50), is both sufficient and necessary to induce KSHV
lytic replication from latency through activation of the lytic
gene expression cascade (15, 43, 70). RTA strongly activates
expression of many KSHV lytic genes, including polyadenyl-
ated nuclear (PAN) RNA, ORFK8, ORF57, viral G protein-
coupled receptor, vIRF1, K1, gB, and itself (4, 10, 36, 41, 42,
65, 70, 79, 88). Although the nature of the detailed mechanism
of RTA-mediated transactivation is unclear, evidence suggests
that various cellular factors play important roles in RTA-me-
diated transactivation. Several factors such as RBP-J/CBF1,
STAT3, CBP (CREB-binding protein), C/EBP, histone deacety-
lase complex (HDAC), SWI/SNF, and IRF-7 have been found
to associate with RTA and modulate its transcriptional activity
(16–18, 32, 61, 78, 81, 85).
Our laboratory previously identified a KSHV-RTA binding
protein (K-RBP) by use of a yeast two-hybrid screening of a
B-cell cDNA library (80). This cellular protein, referred to as
the human hypothetical protein MGC2663 or ZnF426, is en-
coded on human chromosome 19 (19p13.2; GenBank acces-
sion number AC008567). K-RBP expression could be detected
in several primate cell lines, including BC-3, BJAB, 293, and
CV-1 cells (80). Coimmunoprecipitation and pull-down assays
have further demonstrated that K-RBP interacts with RTA
both in vivo and in vitro (80). K-RBP is 554 amino acids (aa)
in size and displays sequence similarity to members of the
Kruppel-associated box (KRAB)-containing zinc finger pro-
teins, suggesting that K-RBP is a member of the KRAB-con-
taining zinc finger protein family of transcriptional modulators.
KRAB-containing zinc finger proteins make up the largest
single family of transcriptional regulators in mammalian cells
(3). All KRAB-containing zinc finger proteins contain one or
two KRAB domains located near the N terminus and 4 to 30
C2H2 zinc-finger motifs at the C terminus (3, 58). The KRAB
domain has been shown to be a protein-protein interaction
module and a transcriptional repression domain. It contains
conserved boxes known as A and/or B (b) and/or C boxes, with
each KRAB domain between 50 and 75 aa in length (3, 37, 38,
45, 73). The KRAB-A box contains the transcriptional repres-
sion activity, while the B and C boxes are dispensable for
repression (1, 38, 44, 77). The repression by KRAB domain has
been shown to depend on the physical interaction with a pro-
tein known as TIF1 (transcription intermediary factor 1)/
KAP1 (KRAB-associated protein-1)/KRIP-1 (KRAB-A inter-
acting protein) (12, 26, 48). TIF1 functions as corepressor
and enhances KRAB-mediated repression. The repression ac-
tivity of a KRAB-containing protein/TIF1 complex at the
DNA regulatory region was shown to be a result of the recruit-
ment of cellular factors to the transcriptional complex. These
factors include heterochromatin protein 1 (HP1) family, a fam-
ily of nonhistone heterochromatin-associated proteins with
gene-silencing function, HDAC, and SETDB1, a SET domain-
containing protein that methylates lysine 9 of histone H3 (30,
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52, 56, 59, 63, 64). Due to the repression activity of KRAB
domain, most of the characterized KRAB-containing zinc fin-
ger proteins such as ZBRK1, SZF1, and KS1 have been dem-
onstrated to function as transcriptional repressors (14, 57, 87).
They function by binding to specific DNA sequences through
their zinc finger motifs and mediating transcriptional repres-
sion through the KRAB domain (37, 82). Studies have also
shown that KRAB-containing proteins can repress transcrip-
tion indirectly via interacting with other proteins. For example,
retinoblastoma (RB)-associated KRAB protein, RbaK, has
been shown to interact with RB to repress E2F-dependent
gene expression and inhibit DNA synthesis (67). Krim-1B
(KRAB box protein interacting with Myc-1B) has been shown
to interact with c-Myc and repress c-Myc-dependent transcrip-
tional activation (20). VHL (Von Hippel-Lindau)-associated
KRAB-A domain-containing protein (VHLaK) has been shown
to interact with VHL and repress HIF-1 (hypoxia-inducible fac-
tor-1)-mediated transcriptional activity (31).
Recently, a number of studies have shown that KRAB-con-
taining zinc finger proteins play important roles in cell differ-
entiation and organ development, including in bone, heart,
sperm, and hematopoietic cells, and regulate their physiologi-
cal processes even though the targeted genes directly con-
trolled by KRAB-containing zinc finger proteins have not been
found (21, 24, 39, 72, 84). For example, the KRAB-containing
zinc finger protein AJ18 was found to be involved in bone
development (24). In addition, several studies have shown that
KRAB-containing zinc finger proteins are involved in regulat-
ing viral replication and transcription. ZBRK1, along with its
corepressor TIF1, was found to interact with the Epstein-
Barr virus replication protein BBLF2/3, and this complex pro-
vides an origin-tethering function for Epstein-Barr virus repli-
cation (34). Another KRAB-containing zinc finger protein,
OTK18, was found to be a human immunodeficiency virus type
1-inducible transcriptional suppressor and to suppress human
immunodeficiency virus type 1 replication (7, 8). These find-
ings indicate that KRAB-containing zinc finger proteins have
diverse functions in regulating different cellular activities and
virus-cell interactions through direct binding to the promoters
of the target genes or indirectly by interacting with other pro-
teins.
To understand the normal cellular function of K-RBP and
its role in RTA-mediated transcriptional activation and KSHV
lytic replication, we further characterized K-RBP. We demon-
strated that this putative KRAB-containing zinc finger protein
exhibits transcriptional repression function and interacts with
the corepressor TIF1. Moreover, we found that K-RBP can
modulate RTA-mediated transcriptional activation and sup-
press KSHV reactivation from latency. These findings suggest
that K-RBP, the KRAB-containing transcriptional repressor, is
involved in the modulation of KSHV-RTA activity and plays a
role in maintaining the balance between latency and lytic rep-
lication of KSHV.
MATERIALS AND METHODS
Plasmids. All clones with inserts that were amplified by PCR were confirmed
by DNA sequence analysis. RTA expression plasmid pCMV-Tag50, which en-
codes a Flag-tagged RTA, was described previously (79, 80). K-RBP expression
plasmids pcDNAK-RBP (pcDNA-MGC2663), which encodes the full-length hu-
man MGC2663 cDNA, and pHAK-RBP (pHA-MGC2663), which encodes a
hemagglutinin (HA)-tagged K-RBP, were also described previously (80). pHAK-
RBP1-213 and pHAK-RBP214-554, deletion clones of K-RBP encoding HA-
tagged K-RBP segments from aa 1 to 213 and aa 214 to 554, respectively, were
constructed by inserting the corresponding DNA fragments into the mammalian
expression vector pCMVHA (Clontech). Reporter plasmids p57Pluc1 and
pK8Pluc, containing PCR-cloned promoter regions of KSHV ORF57 (from
nucleotide [nt] 81556 to 82008) and ORFK8 (from nt 73851 to 74849), were
described elsewhere (80). Reporter plasmid pPANPluc contains the promoter
region of PAN RNA (from nt 28461 to 28681) inserted into the upstream portion
of the luciferase reporter gene of pGL3-Basic vector (Promega). The -galac-
tosidase (-Gal) expression plasmid pCMV- (Clontech) was used for the nor-
malization of transfection efficiency.
The Matchmaker two-hybrid system 3 vectors used in yeast two-hybrid assay
were purchased from Clontech. The constructs pGBKK-RBP, pGBKK-RBP42-
98, pGBKK-RBP1-213, and pGBKK-RBP214-554, which encode full-length K-
RBP and aa 42 to 98, aa 1 to 213, and aa 214 to 554 of K-RBP fused to GAL4
DNA-binding domain (GAL4BD), respectively, were generated by inserting the
corresponding DNA fragments into pGBKT7 vector, which encodes the yeast
GAL4 N-terminal 147-aa DNA binding domain located upstream of the inserted
DNA. The yeast expression plasmid pGADTIF1, which encodes TIF1 fused to
a GAL4 activation domain, was generated by inserting the DNA fragment into
pGADT7. The expression clone pCMVTIF1Flag encoding the TIF1 was
obtained from Walter Schaffner (Universita¨t Zu¨rich, Zu¨rich, Switzerland)
(48). pGADTIF11-423 and pGADTIF1442-835, which encode TIF1 aa 1
to 423 and aa 442 to 835 fused to GAL4AD, were subcloned from pGADTIF1
by use of suitable restriction sites. Clones pHATIF1, pHATIF11-423, and
pHATIF1442-835 encode HA-tagged TIF1 and the deletion mutants. The
corresponding DNA fragments of TIF1 were obtained from pGADTIF1 and
inserted into pCMVHA vector. The expression plasmids pHACBP, which en-
codes HA-tagged CBP, and pCMVp300, which encodes p300, were kind gifts
from Clinton Jones (University of Nebraska, Lincoln, NE).
The mammalian pCMVBD vector (Stratagene) was used in GAL4BD fusion
protein/GAL4-luciferase reporter assays to determine the transcriptional activity
of K-RBP. The mammalian GAL4BD fused expression clones pBDK-RBP,
pBDK-RBP42-98, pBDK-RBP1-213, pBDK-RBP99-213, and pBDK-RBP99-554
encode full-length K-RBP and aa 42 to 98, aa 1 to 213, aa 99 to 213, and aa 99
to 554 of K-RBP, respectively. They were generated by cloning the correspond-
ing DNA fragments into the pCMVBD vector. Clone pBDKOX1KRAB, which
encodes aa 1 to 90 of the KOX1 KRAB domain, was a kind gift from Frank J.
Rauscher III (University of Pennsylvania, Philadelphia, PA) (55). The reporter
plasmid pFR-luc, which contains five copies of GAL4 binding element located
upstream of a firefly luciferase reporter gene, was purchased from Stratagene.
Antibodies. K-RBP antibody was prepared by immunizing a rabbit with Esch-
erichia coli-expressed recombinant K-RBP, and the RTA antibody was prepared
by immunizing a rabbit with baculovirus-expressed recombinant RTA from in-
sect cells (Lampire Biological Laboratories). The rabbit anti-TIF1 polyclonal
antibody was purchased from Santa Cruz Biotechnology. The mouse anti--
tubulin monoclonal antibody was purchased from Sigma. The mouse anti-Flag
M2 monoclonal antibody was purchased from Stratagene. The rabbit anti-HA
polyclonal antibody and mouse anti-His monoclonal antibody were purchased
from Clontech. The rat anti-LANA monoclonal antibody was purchased from
Advanced Biotechnologies Inc. The mouse anti-K8 monoclonal antibody was
purchased from Novus Biologicals. The mouse anti-K8.1 monoclonal antibody
was obtained from Bala Chandran (Rosalind Franklin University, Chicago, IL).
Yeast two-hybrid assay. The yeast two-hybrid assay was performed using
Matchmaker two-hybrid system 3 (Clontech). K-RBP and its truncated mutants
were fused to the GAL4BD of the pGBKT7 plasmid. The TIF1 and its mutants
were fused to the GAL4AD of the pGADT7 plasmid as described above. Sac-
charomyces cerevisiae AH109 was used as the reporter host strain.
Cell culture, transfection, and luciferase assays. Human 293T cells were
grown in Dulbecco’s modified Eagle medium (DMEM, Gibco BRL) supple-
mented with 10% fetal bovine serum (FBS; Gibco BRL) and 100 g/ml penicil-
lin-streptomycin (Mediatech) at 37°C with 5% CO2. In each well of a six-well
plate, 3 105 293T cells were transfected with 1 to 2 g of total DNA mixed with
2 l of Lipofectamine reagent (Invitrogen) in DMEM according to the manu-
facturer’s recommendations. The total DNA amount used in each transfection
was normalized by adding control plasmids. Fresh DMEM containing penicillin-
streptomycin and supplemented with 20% FBS was added to the transfected cells
at 7 h posttransfection, and cells were grown for an additional 17 h. Luciferase
activities were determined by use of a Luciferase assay system (Promega) ac-
cording to the manufacturer’s procedure. Data were averaged from the results of
multiple transfections performed in at least three independent experiments. The
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transfection efficiency for each experiment was normalized by cotransfecting
-Gal expression plasmid pCMV- as the internal control.
Stealth small interfering RNA (siRNA) was designed using Invitrogen’s
BLOCK iT RNAi Designer. The sequences of siRNA targeting K-RBP are
located at positions 1462 to 1486 (GenBank accession number BC001791) as
follows: sense, GCCUUUGCAGUUUCCUCAAAUCUUA; and antisense,
UAAGAUUUGAGGAAACUGCAAAGGC. The sequences of siRNA target-
ing TIF1 are located at positions 740 to 764 (GenBank accession number
NM_005762) as follows: sense, CAGUGCUGCACUAGCUGUGAGGAUA;
and antisense, UAUCCUCACAGCUAGUGCAGCAGUG. The control siRNA
sequences used were as follows: sense, GGCGUCAAUCCGACAGUUAU
GUUAU; and antisense, AUAACAUAACUGUCGGAUUGACGCC. Trans-
fection of siRNA into 293T cells was conducted using Lipofectamine 2000 (In-
vitrogen) according to the manufacturer’s procedure.
BCBL-1 is a KSHV-positive primary effusion lymphoma cell line. TRExBCBL-
1RTA is a BCBL-1 cell line carrying a tetracycline-(or doxycycline-) inducible
RTA gene (50) and was provided by Jae Jung (Harvard Medical School, Boston,
MA). This cell line was maintained in RPMI 1640 (Gibco BRL) containing 10%
FBS, 100 g/ml penicillin-streptomycin, and 200 g/ml hygromycin B at 37°C
with 5% CO2. The transfection of TRExBCBL-1RTA cells was carried out using
a Nucleofector device (Amaxa) according to the manufacturer’s procedure. The
transfection efficiency in TRExBCBL1RTA cells was found to be around 50%
using this method.
Vero cells infected by rKSHV.219 virus were provided by Jeffrey Vieira (Uni-
versity of Washington, Seattle, WA) (76). The cells were maintained in DMEM
supplemented with 10% FBS, 100 g/ml streptomycin-penicillin, 2 mM L-glu-
tamine, and 5 g/ml puromycin in a humidified incubator at 37°C with 5% CO2.
A recombinant baculovirus expressing the KSHV-RTA was also obtained from
Jeffery Vieira, and its use in the generation of rKSHV.219 virus was carried out
as described earlier (76). Transfection of K-RBP siRNA into Vero cells infected
with rKSHV.219 was conducted using Lipofectamine 2000 (Invitrogen) accord-
ing to the manufacturer’s procedure, and the transfection was carried out two
times within 24 h to obtain efficient knockdown.
Coimmunoprecipitation. 293T cells were transfected with various combina-
tions of expression plasmids. At 48 h posttransfection, the cells were lysed in 0.5
ml ice-cold immunoprecipitation (IP) buffer (1% Nonidet P-40, 0.5% sodium
deoxycholate, and 1 mM phenylmethylsulfonyl fluoride in phosphate-buffered
saline). After centrifugation at 16,000  g for 10 min, the cell lysates were
precipitated with 2 to 3 g of specific antibodies and incubated overnight at 4°C.
Protein G beads (Amersham) (20 l) were then added and incubated for 2 h.
The beads were then washed four times with IP buffer. The immunoprecipitated
proteins were heated in sample buffer, analyzed by 7 to 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and transferred to a
polyvinylidene difluoride membrane (Amersham) for Western blot analysis.
Western blot analysis. The transferred polyvinylidene difluoride membrane
was blocked with 3 to 5% nonfat dry milk in TBST (50 mM Tris [pH 7.5], 200
mM NaCl, 0.05% Tween 20) at room temperature for 1 h. It was then incubated
with the primary antibody in the same TBST buffer containing milk for 1 h at
room temperature. The membrane was washed three times with TBST for 10 to
15 min each time, incubated with horseradish peroxidase-conjugated secondary
antibody at room temperature for 1 h, washed three times with TBST, treated
with SuperSignal detection reagents (Pierce), and then exposed to Kodak light
film.
RNA extraction and RT-PCR. Total cellular RNA was prepared using an
RNeasy kit (QIAGEN) according to the manufacturer’s procedure. Total RNA
(1 g) was used for reverse transcription (RT) using oligo(dT) as a primer, and
the reverse-transcribed products were then used as templates for PCR amplifi-
cation with gene-specific primers.
PCR analysis of virus progeny. The supernatant of Vero cells infected with
rKSHV.219 was collected after RTA induction and centrifuged at 2,000 rpm to
spin down cell debris. The supernatant was then collected, and the viral particles
were concentrated through a 20% sucrose gradient at 17,000 rpm and 4°C for 2 h.
Virus pellets were resuspended in 200 l of 0.2 phosphate-buffered saline,
digested by DNase I for 1 h at 37°C to remove exogenous DNA, and heated to
95°C for 15 min and then 56°C for 1 h with proteinase K treatment (100 g/ml).
The enzyme was inactivated by treatment at 95°C for 30 min; the DNA was then
purified by use of a QIAGEN PCR purification kit and eluted by elution buffer.
Viral DNA solution (1 l) was used for PCR amplification of the KSHV-specific
fragment located in ORF26, and the amplicon was analyzed using 1.5% agarose
gel. Real-time PCR was performed according to the manufacturer’s protocol
using TaqMan chemistry (Applied Biosystems). The relative amounts of DNA
were calculated using Bio-Rad iCycler software (version 3.1; Bio-Rad Labora-
tories).
Protein stability analysis. For the analysis of the protein stability, approxi-
mately 3  106 293T cells were transfected with plasmids expressing different
proteins of interest in the presence of 75 g/ml cycloheximide (Sigma) for 24 h
after transfection. The transfected cells were harvested at various time points
after cycloheximide treatment, and the cell lysates were prepared. Western blot
analysis was then used to determine the amount of proteins at various time points
with specific antibodies.
The stability of protein was also determined by pulse-chase analysis. Approx-
imately 1  106 transfected human 293T cells were incubated in methionine- and
cysteine-free DMEM (Gibco BRL) for 40 min at 24 h posttransfection. Medium
was then removed and replaced with fresh methionine-free DMEM containing
200 Ci/ml EXPRE35S35 protein labeling mix (PerkinElmer Life Sciences). Cells
were labeled for 30 min at 37°C and washed twice with DMEM, and complete
DMEM with 10% FBS was added. Cells were harvested at various time points
and lysed in 500 l ice-cold IP buffer for 1 h. The lysates were then centrifuged
at 16,000  g for 15 min, and equal counts per minute of the lysates were
immunoprecipitated with specific antibody and protein G beads. The beads were
washed four times with IP buffer, suspended in sample buffer, and then separated
by SDS-PAGE. The gel was then analyzed by fluorography and exposed to film
overnight. The band intensities were quantitated with NIH Image software.
Nucleotide sequence accession number. The GenBank accession number for
the KSHV sequences reported in this study is KSU75698.
RESULTS
K-RBP exhibits transcriptional repression activity in an
HDAC-independent manner. We previously identified a KSHV-
RTA binding protein named K-RBP by yeast two-hybrid screen-
ing using a B-cell cDNA library (80). K-RBP is a novel cellular
protein generated from a multiply spliced message derived from
the human chromosome 19 clone CTC-543D15 (GenBank acces-
sion number AC008567), and the normal cellular function of
K-RBP is unknown. K-RBP contains a KRAB domain and mul-
tiple C2H2 zinc finger motifs, including one nontypical C2H2 zinc
finger and 11 typical C2H2 zinc fingers, suggesting that it belongs
to the KRAB-containing zinc finger protein family (Fig. 1A).
Since most members of this protein family have been shown to
function as transcriptional repressors through their KRAB do-
mains and bind DNA via their zinc finger motifs (14, 57, 75, 87),
we anticipated that K-RBP functions as a transcriptional repres-
sor and mediates repression through its KRAB domain.
To investigate whether K-RBP possesses transcriptional re-
pression function we used the GAL4BD fusion protein–GAL4-
luciferase reporter system, since the potential DNA-binding
sequence of K-RBP zinc finger motifs is unknown. This system
relies on GAL4BD fusion protein binding to the GAL4 bind-
ing element in the promoter regulatory region of luciferase
reporter vector pFR-Luc, which contains five copies of GAL4
binding element (Fig. 1B) and has been used for the analysis of
transcription factors in mammalian cells (51, 60, 86). We gen-
erated pBDK-RBP, a full-length GAL4BD and K-RBP fusion
protein expression construct, and cotransfected it with pFR-
Luc. The presence of pBDK-RBP was found to strongly re-
press the luciferase reporter activity at a level higher than the
repression induced by the well-characterized KOX1 KRAB
domain that was used as a positive control (Fig. 1C) (40, 49).
As expected, the K-RBP construct pcDNAK-RBP did not re-
press the luciferase reporter gene expression, since it is un-
likely that K-RBP itself will bind to the GAL4 elements of
pFR-luc in the absence of GAL4BD. The expression of each
construct was verified by Western blotting using the specific
antibodies (Fig. 1D). These data suggest that K-RBP functions
as a transcriptional repressor when tethered to the target pro-
moter.
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To determine whether the KRAB domain of K-RBP medi-
ates the repression, we analyzed the putative KRAB domain
from aa 42 to 98 and aligned it with several other KRAB
domains by use of the alignment program of Vector NTI suite
8 (Invitrogen) to determine its similarity to the KRAB domains
of other transcriptional repressors. The KRAB domains of
ZNF40, ZNF133, ZNF140, KOX1, KID-1, ZBRK1, RBaK1,
Hkr18, and Hkr19 (GenBank accession numbers P15822,
AAH01887, AAH40561, AAH24182, AAH47105, AAG17439,
AAF43389, Q9HCG1, and Q96JC4, respectively) were used in
this comparison (Fig. 2A). These domains contain KRAB A
and B boxes (37), and the alignment showed that K-RBP
KRAB domain contains almost all the conserved amino acids
in the KRAB domain (Fig. 2A) (2), indicating that the KRAB
domain of K-RBP belongs to the KRAB AB subfamily. Since
all the KRAB domains identified have been shown to repress
transcription (75), it is likely that KRBP KRAB domain is
responsible for the suppressive function of K-RBP.
To verify that the KRAB domain of K-RBP is responsible
for the repression function of K-RBP, several GAL4BD and
K-RBP deletion fusion proteins were generated. Both pBDK-
RBP1-213 and pBDK-RBP42-98 express the KRAB domain.
Clone pBDK-RBP99-554 expresses the 12 zinc finger motifs
but lacks the KRAB domain, and clone pBDK-RBP99-213
expresses the domain that contain only the nontypical C2H2
zinc finger motif (Fig. 2B). As shown in Fig. 2C, the presence
of pBDK-RBP1-213, pBDK-RBP42-98, or pBDK-RBP re-
pressed the luciferase reporter gene expression, while the pres-
ence of pBDK-RBP99-554 and pBDK-RBP99-213 did not.
The presence of pBDK-RBP99-213 was found to activate tran-
scription four- to fivefold. The full-length K-RBP construct
pBDK-RBP exhibited the strongest activity and repressed
transcription by more than 90%, while the KRAB construct
pBDK-RBP42-98 expressing the domain (42 to 98 aa) alone
exhibited the weakest activity and repressed transcription by
about 50% (Fig. 2C). The repression by K-RBP and the KRAB
domain (K-RBP42-98) was found to be dose dependent (Fig.
2E and F). These data suggest that the KRAB domain is
responsible for the repression function of K-RBP but that
optimal repression requires a region other than the KRAB
domain of K-RBP. The inability of some of the constructs to
repress was not due to defects at the protein expression level,
since the presence of all the GAL4BD-fused K-RBP deletion
proteins was verified by Western blotting (Fig. 2D).
The repression function of some KRAB-containing zinc fin-
ger proteins was shown to involve HDACs which remove the
acetyl groups that silence transcription (64), whereas others,
such as KOX1, mediate repression through an HDAC-inde-
pendent mechanism (40). We found that HDACs have little
effect on the repression function of K-RBP, because the addi-
tion of trichostatin A, a potent inhibitor of HDACs, has little
effect on the K-RBP repression activity (Fig. 3A). In addition,
the overexpression of CBP and p300 encoded by pHACBP and
pCMVp300, which possess histone acetyltransferase activities
and are antagonists for HDACs (53), did not relieve the K-
RBP-mediated repression of the reporter gene expression
(Fig. 3B). In contrast, the presence of CBP and p300 expres-
sion enhances K-RBP-mediated repression (Fig. 3B). This may
be due to overexpression of CBP and p300 altering the cellular
environment and leading to more K-RBP protein being ex-
pressed. This was in fact the case, as demonstrated by the
results of Western blot analysis (Fig. 3C). Taken together, the
results described above suggest that K-RBP-mediated repres-
sion is HDAC independent.
K-RBP interacts with TIF1, a corepressor of KRAB-con-
taining zinc finger proteins. The KRAB domains from several
KRAB-containing zinc finger proteins have been shown to
physically interact with TIF1, a transcriptional corepressor
for KRAB-containing proteins (1, 2, 26, 31, 47, 48). Since
K-RBP is a KRAB-containing transcriptional repressor and
contains the crucial amino acids (DV and MLE) needed for
TIF1 interaction (Fig. 2A) (12), we then examined whether
K-RBP also associates with TIF1 by use of the yeast two-
FIG. 1. K-RBP is a transcriptional repressor. (A) Schematic representation of K-RBP, including a putative KRAB domain and 12 zinc finger
motifs. (B) The GAL4BD fusion protein–GAL4-luciferase reporter system. (C) K-RBP exhibits transcriptional repression activity when it is
tethered to the promoter region of reporter plasmid. The expression plasmids pcDNAK-RBP, pBDK-RBP, and pBDKOX1KRAB were trans-
fected into 293T cells along with the reporter plasmid pFR-Luc (0.25 g). Error bars indicate standard deviations. The luciferase activity with
control plasmid was normalized to 100. (D) The proteins expressed by the plasmids used as described for panel C were detected by Western blot
analysis using the indicated antibodies. Asterisks indicate the specific proteins detected.
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hybrid assay. As shown in Table 1, cotransformation of plas-
mids pGBKK-RBP, which expresses GAL4BD-fused K-RBP,
and pGADTIF1, which expresses GAL4AD-fused TIF1, ac-
tivated the expression of reporter genes. The K-RBP domain
that is responsible for the interaction with TIF1 was mapped
to its first 213 aa, a region which contains its KRAB domain,
since clone pGBKK-RBP214-554, which expresses the zinc fin-
ger domain of K-RBP, was not active when cotransformed with
pGADTIF1. However, we could not demonstrate the inter-
action between K-RBP1-213 and TIF1 directly by yeast two-
hybrid analysis, since clones pGBKK-RBP1-213, which expresses
the first 213 aa, and pGBKK-RBP42-98, which expresses the
KRAB domain, were found to activate the reporter gene by
themselves. The domain consisting of the first 423 aa of TIF1
(clone pGADTIF11-423), which has previously been shown
to interact with other KRAB domains, can interact with K-
RBP (48) (Table 1). No activation was observed with either
pGADTIF1 or pGBKK-RBP cotransformed with the control
plasmids (pGBKT7 or pGADT7).
The interaction between K-RBP and TIF1 was further
confirmed by coimmunoprecipitation in 293T cells. Flag-tagged
TIF1 protein encoded by pCMVTIF1Flag could be coim-
FIG. 2. Transcriptional repression activity of K-RBP. (A) Comparison of putative K-RBP KRAB domain with KRAB domains from other
KRAB-containing zinc finger proteins (ZNF40, ZNF133, ZNF140, KOX1, KID-1, ZBRK1, RBaK1, Hkr18, and Hkr19; GenBank accession
numbers P15822, AAH01887, AAH40561, AAH24182, AAH47105, AAG17439, AAF43389, Q9HCG1, and Q96JC4, respectively). KRAB-A and
KRAB-B boxes are indicated. Dashes (-) show gaps among the aligned sequences. Conserved amino acids of KRAB domain are shaded, and a
consensus sequence is shown at the bottom. The crucial amino acids for TIF1 interaction are underlined. Alignment was performed using Vector
NTI suite 8 (Invitrogen). (B) Schematic diagram of K-RBP deletion mutants used to determine the domain responsible for the repression activity
of K-RBP. (C) Transcriptional activity of K-RBP mutants. Different GAL4BDK-RBP mutant constructs were cotransfected with the reporter
plasmid pFR-luc (0.25 g) into 293T cells, and luciferase activities were measured at 24 h after transfection. Error bars indicate standard
deviations. The luciferase activity with control plasmid was normalized to 100. (D) Western blot analysis using antibody against GAL4BD with
lysates of cells transfected with different K-RBP mutants to determine the expression of the K-RBP mutant proteins. Asterisks indicate the specific
proteins detected. (E) The repression activity of K-RBP is dose dependent. Various amounts of pBDK-RBP expression plasmid were cotransfected
with reporter plasmid pFR-luc (0.25 g) into 293T cells. The results of Western blot analysis of the expression of GAL4BDK-RBP by use of
antibody against GAL4BD are shown at the bottom. Error bars indicate standard deviations. The luciferase activity with control plasmid was
normalized to 100. (F) The repression activity of KRAB domain is dose dependent. Experiments were carried out as described for panel E, except
pBDK-RBP42-98 plasmid was used.
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munoprecipitated with HA-tagged K-RBP protein encoded by
pHAK-RBP in the presence of anti-HA antibody but not with
pCMVHA, which only expresses the HA tag (Fig. 4A). More-
over, Flag-tagged TIF1 protein could be coimmunoprecipi-
tated by an HA-tagged K-RBP1-213 containing the KRAB
domain, whereas an HA-tagged construct pHAK-RBP214-554
containing the K-RBP zinc finger motifs failed to coimmuno-
precipitate TIF1 (Fig. 4A). This finding is consistent with the
yeast two-hybrid results and indicates that the KRAB domain
mediates the interaction between K-RBP and TIF1. Simi-
larly, coimmunoprecipitation also demonstrated that HA-
tagged K-RBP and HA-tagged K-RBP1-213 could be coimmu-
noprecipitated with Flag-tagged TIF1 protein in the presence
of anti-Flag antibody (Fig. 4B). Furthermore, endogenous K-
RBP protein was shown to interact with HA-tagged TIF1 by
using anti-K-RBP antibody to immunoprecipitate K-RBP in
293T cells transfected with pHATIF1. The HA-tagged TIF1
protein was detected by Western blot analysis using anti-HA
antibody as a probe after anti-K-RBP precipitation. The pre-
immune serum for K-RBP did not precipitate the HATIF1
(Fig. 4C). Taken together, these results demonstrate that K-
RBP can bind to the corepressor TIF1, using it as a corepres-
sor, in similarity to what was observed with other KRAB-
containing zinc finger proteins.
TIF1 stabilizes K-RBP. During the analysis of K-RBP, a
much higher level of K-RBP protein in the presence of over-
expressed TIF1 was observed (Fig. 5A, left panel), but the
level of K-RBP mRNA remained unchanged, as determined by
semiquantitative RT-PCR (Fig. 5A, right panel). The results
described above suggest that TIF1 may stabilize K-RBP and
extend its half-life. To confirm this observation, we examined
the temporal levels of K-RBP in 293T cells which were co-
transfected with pHAK-RBP and pCMVTIF1Flag in the
presence of cycloheximide treatment to prevent new protein
synthesis. The K-RBP expression was determined by Western
blot analysis using anti-K-RBP antibody (Fig. 5B). -Tubulin,
which has a long half-life, was used as a control. The stability
of K-RBP was found to be enhanced in the presence of over-
expressed TIF1. In the absence of TIF1, K-RBP protein
could not be detected at 90 min after cycloheximide treatment,
whereas in the presence of TIF1, K-RBP protein could still be
detected at 450 min. This result was further confirmed by
pulse-chase analysis using 293T cells transfected with pHAK-
RBP either with or without pCMVTIF1Flag. As shown in
Fig. 5C, K-RBP has a much longer half-life when coexpressed
with TIF1. The half-life of K-RBP was approximately 30 min
in the absence of TIF1, while its half-life was estimated to be
up to 150 min in the presence of TIF1. Our results thus
support the notion that TIF1 extends the half-life of K-RBP.
We next sought to test whether the interaction between TIF1
and K-RBP is sufficient for K-RBP stabilization by use of various
TIF1 mutants (Fig. 5D). The TIF1 mutant pHATIF11–
423, which retains the interaction domain with K-RBP, failed
to stabilize K-RBP. The TIF1 mutant pHATIF1442–835,
which does not interact with K-RBP, also failed to stabilize
K-RBP. Our result suggests that the interaction between K-
RBP and TIF1 alone is not sufficient to protect K-RBP from
degradation.
K-RBP modulates RTA-mediated transcriptional activa-
tion of several KSHV promoters. Since K-RBP was first
identified via its interaction with RTA, we tested the effect
of K-RBP on RTA-induced transactivation of several viral
promoters in 293T cells. As observed earlier (80), K-RBP
was found to enhance RTA-mediated transactivation of
ORFK8 (pK8Pluc) and ORF57 (p57Pluc1) promoters when
FIG. 3. The repression activity of K-RBP is HDAC independent. (A) The effect of HDAC inhibition on transcriptional repression activity of
K-RBP. 293T cells were transfected with the indicated plasmids and pFR-luc (0.25 g). At 14 h posttransfection, the cells were treated with
trichostatin A (TSA) or vehicle control (dimethyl sulfoxide) for another 20 h and then lysed, and luciferase activities were measured. (B) Effect
of overexpression of pCMVp300 or pHACBP on the repression activity of K-RBP. 293T cells were transfected with indicated plasmids along with
pFR-luc (0.25 g). Luciferase activities were measured at 24 h after transfection. Error bars indicate standard deviations. The luciferase activity
with control plasmid pCMVBD was normalized to 100. (C) Western blot analysis of cell lysates prepared from the transfected cells as described
for panel B to detect the expression of pBDK-RBP by use of antibody against K-RBP.
TABLE 1. Reporter gene expression by yeast (AH109) transformantsa
Plasmid
with GAL4BD
Plasmid
with GAL4AD
LacZ
expressionb
His/Ade
expressionc
pGBKK-RBP pGADTIF1  
pGBKK-RBP pGADTIF11-423  
pGBKK-RBP pGADTIF1442-835  
pGBKK-RBP214-554 pGADTIF1  
pGBKT7 pGADTIF1  
pGBKT7 pGADTIF11-423  
pGBKT7 pGADTIF1442-835  
pGBKK-RBP pGADT7  
pGBKK-RBP214-554 pGADT7  
pGBKK-RBP1-213 pGADT7  
pGBKK-RBP42-98 pGADT7  
a AH109 was cotransformed with the indicated GAL4BD and GAL4AD plas-
mids. Cotransformants were selected using nutrition selection markers for the
vectors. The phenotypes of the colonies were analyzed by filter -Gal assays and
by their growth on synthetic dropout medium (SD) plates lacking His and Ade.
b , intense blue color development within 3 h in the filter paper -Gal
assays; , intense blue color development within 6 h in the filter paper -Gal
assays; , clone was unable to develop color in 8 h.
c , colonies appeared after 2 days of incubation at 30°C on SD plates
lacking His and Ade; , colonies appeared after 3 days; , no growth.
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expressed at low concentrations (Fig. 6 A and B) (80).
However, K-RBP was found to inhibit RTA-mediated trans-
activation of KSHV ORFK8 and ORF57 promoters when
increasing amounts of K-RBP expression plasmid were
added (Fig. 6A and B). More than 50% inhibition was ob-
served when the highest amount of K-RBP was tested. The
repression was also observed with the KSHV PAN promoter
(pPANPluc), and K-RBP suppressed RTA-mediated PAN
promoter activation by 30% (Fig. 6C). The repression is not
due to an effect on RTA expression, because K-RBP was
found to have no effect on RTA expression level, as deter-
mined by Western blot analysis (Fig. 6D). We also tested
whether K-RBP can suppress RTA-mediated transactiva-
tion in Vero cells and found that overexpression of K-RBP
can indeed repress RTA-mediated transactivation of PAN
(Fig. 6E), ORF57, and K8 promoters (data not shown).
FIG. 4. Coimmunoprecipitation assays to demonstrate the interaction between K-RBP and corepressor TIF1. (A) TIF1 can be coimmu-
noprecipitated with K-RBP. Lysates prepared from 293T cells transfected with the indicated plasmids were subjected to immunoprecipitation with
an anti-HA antibody followed by anti-Flag immunoblotting. (B) K-RBP and K-RBP1-213 coimmunoprecipitated with TIF1. Lysates prepared
from 293T cells transfected with the indicated plasmids were subjected to immunoprecipitation with an anti-Flag antibody followed by anti-HA
immunoblotting. (C) Endogenous K-RBP interacts with TIF1. Lysate from 293T cells transfected with pHATIF1 plasmid was subjected to
immunoprecipitation using anti-K-RBP antibody or preimmune serum followed by immunoblotting with anti-HA antibody. I represents input, C
represents coimmunoprecipitation. WB, Western blotting.
FIG. 5. TIF1 stabilizes K-RBP. (A) Left panel, Western blot analysis of K-RBP in lysates made from 293T cells transfected with pHAK-RBP
in the presence or absence of pCMVTIF1Flag. Equivalent amounts of proteins were loaded in each lane, as confirmed by Western blot analysis
using -tubulin as a control. Right panel, RT-PCR analysis of K-RBP RNA expression isolated from transfected cells represented in the left panel.
Equivalent amounts of RNA were used in RT-PCR for each experiment, as confirmed by RT-PCR employing the GAPDH gene, which was used
as an internal control. (B) The effect of TIF1 on K-RBP upon cycloheximide (CHX) treatment. The 293T cells transfected with pHAK-RBP in
the presence of control plasmid or pCMVTIF1Flag were harvested at different time points after pretreatment with 75 g/ml cycloheximide and
analyzed by Western blotting. The K-RBP expression levels were analyzed with anti-K-RBP antibody. -Tubulin was used as an internal control.
(C) The effect of TIF1 on the stability of K-RBP, as measured by pulse-chase analysis. The results of pulse-chase analysis of [35S]methionine-
radiolabeled 293T cells transfected with pHAK-RBP in the presence of control plasmid or pCMVTIF1Flag are presented. Cells were radiola-
beled with 200 Ci/ml [35S]methionine for 30 min and chased for the indicated times with unlabeled methionine. Lysates were immunoprecipitated
with polyclonal anti-HA antibody. The graph depicts densitometric analysis of a representative experiment, the results of which indicate that
K-RBP has an estimated half-life of 30 min in the absence of TIF1 and of 150 min in the presence of TIF1. The K-RBP bands were expressed
as percentages of intensities, with band intensity at time 0 equal to 100%. The single asterisks indicate K-RBP protein, while the double asterisks
indicate a nonspecific cellular protein band which was used as the internal loading control. (D) Western blot analysis of GAL4BDK-RBP in lysates
of 293T cells transfected with pBDK-RBP in the presence of pCMVHA, pHATIF1, pHATIF11–423, or pHATIF1442–835. Equivalent
amounts of proteins were loaded in each lane, as confirmed by Western blot analysis using -tubulin as an internal control.
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TIF1 participates in the repression of RTA-mediated
transactivation of KSHV promoters. Both TIF1 and RTA
interact with K-RBP, and TIF1 is a potential corepressor of
K-RBP; therefore, we hypothesized that TIF1 may also be
involved in regulating RTA-mediated transactivation, possibly
indirectly via its interaction with K-RBP. We then examined
the effect of TIF1 on RTA-mediated transactivation of
KSHV ORFK8, ORF57, and PAN promoters. Overexpression
of pHATIF1 repressed RTA-mediated transactivation of
both ORFK8 and ORF57 promoters by about 40 to 50% (Fig.
7A, B, E, and F). No significant repression was observed with
the PAN promoter (Fig. 7C), suggesting a promoter-depen-
dent effect. In similarity to K-RBP, TIF1 had no effect on the
RTA protein expression (Fig. 7D). Overexpression of both
TIF1 and K-RBP led to a synergistic effect on the RTA-
mediated transactivation of K8 and ORF57 promoters, with 50
to 70% repression (Fig. 7E and F). This is reflected at the
protein level; the presence of TIF1 led to an increase of
K-RBP protein (Fig. 7G). The presence of TIF1 also led to a
slight enhancement of RTA, but the increase was not observed
consistently. Our results nevertheless suggest that TIF1 and
K-RBP synergize in the suppression of RTA-mediated trans-
activation. TIF1 may be recruited to the promoter by K-RBP,
which then stabilizes K-RBP to enhance its repression of RTA-
mediated transactivation. We also tested whether knockdown
of endogenous K-RBP and TIF1 can lead to an enhancement
of RTA-mediated transactivation of the ORF57 promoter. The
presence of K-RBP-specific siRNA but not control siRNA can
enhance RTA-mediated transactivation, but the effect is only
moderate (Fig. 8A). This suggests that K-RBP is only one of
the many endogenous cellular factors that can suppress RTA-
mediated transactivation. Interestingly, knockdown of TIF1
can enhance RTA-mediated transactivation to a level higher
than that of K-RBP knockdown (Fig. 8A). TIF1 knockdown
in this experiment did not alter K-RBP expression level (Fig.
8B), suggesting that endogenous TIF1 may also modulate
RTA-mediated transactivation of the ORF57 promoter inde-
pendently of K-RBP. Knockdown of both K-RBP and TIF1
can enhance RTA-mediated transactivation to a level higher
than the knockdown of either K-RBP or TIF1 alone.
K-RBP regulates RTA-mediated KSHV reactivation from
latency. The regulation of RTA transactivation by K-RBP on
viral promoters suggests that K-RBP may play a role in KSHV
reactivation. To investigate the effect of K-RBP on KSHV lytic
replication, we used the TRExBCBL-1 RTA cell line (50). In
this cell line, the RTA gene is integrated into the BCBL-1
genome and RTA expression can be induced by tetracycline
(or doxycycline). The cells were transfected with either control
plasmid pcDNA3.1 (Fig. 9A, lane 1) or K-RBP expression
plasmid pcDNAK-RBP (Fig. 9A, lane 2) to overexpress K-
RBP. Interestingly, the expression of the early lytic gene K8
and late lytic gene K8.1 was lower in cells that were overex-
pressing K-RBP. Their expression was reduced by about 30 to
50%, whereas the latent gene LANA was not affected (Fig.
9A). The doxycycline-induced His-tagged RTA protein can be
detected by anti-His antibody, and the total RTA from doxy-
cycline-induced cells can be detected with anti-RTA antibody
(50). K-RBP was detected in both control cells (Fig. 9A, lane
1) and K-RBP expression plasmid-transfected cells (Fig. 9A,
lane 2). His-tagged RTA and total RTA levels were found to
be comparable in both pcDNAK-RBP- and pcDNA3.1-trans-
fected cells upon treatment with doxycycline (Fig. 9A). Cells
FIG. 6. K-RBP can downregulate RTA-mediated transcriptional activation of KSHV promoters. (A) 293T cells were transfected with the
reporter construct pK8Pluc (7.5 ng), a fixed amount (25 ng) of pCMV-Tag50, and increasing amounts (0, 10, 25, 75, 750, and 1,500 ng) of
pHAK-RBP. Luciferase activities were measured at 24 h after transfection. Luciferase reporter activities are expressed as a percentage of
activation, with activation by RTA alone equal to 100%. The error bars indicate standard deviations. (B) Transfection was carried out as described
for panel A, except reporter construct p57Pluc1 (20 ng) was used. (C) Transfection was carried out as described for panel A, except reporter
construct pPANPluc (20 ng) was used. (D) Western blot analysis of RTA expression in the presence of increasing amounts of K-RBP expression.
Lysates of 293T cells transfected with same amount of pCMV-Tag50 and increasing amounts of pHAK-RBP were used in the immunoblotting
using anti-Flag and anti-K-RBP antibodies. The -tubulin level was used to indicate that comparable amounts of each sample were loaded in each
lane. (E) Vero cells were transfected with reporter construct pPANPluc (50 ng), a fixed amount (50 ng) of pCMV-Tag50, and increasing amounts
(0, 100, and 250 ng) of pHAK-RBP. Luciferase activities were measured at 48 h after transfection. Luciferase reporter activities are expressed as
a percentage of activation.
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transfected with K-RBP expression plasmid showed an en-
hanced level of K-RBP, but the enhancement was not substan-
tial. This could be due to the instability of K-RBP and the
difficulty in obtaining more than 50% transfection efficiency in
this TRExBCBL-1 RTA cell line. The level expressed in the
control results represents the normal level of K-RBP. Never-
theless, these results suggest that viral reactivation and the
expression of the lytic viral gene were repressed in the pres-
ence of overexpressed K-RBP.
To further confirm the role of K-RBP in RTA-mediated
KSHV reactivation, siRNA was used to knock down endoge-
nous K-RBP expression in KSHV-infected cells to determine
its effect on viral reactivation. This was carried out by using
Vero cells that were infected by a recombinant green fluores-
cent protein-red fluorescent protein (GFP-RFP) double-la-
beled rKSHV.219 virus (76). In this cell line, KSHV latently
infected cells constitutively express GFP. Upon induction by
RTA, cells that are lytically reactivated express RFP under the
control of the lytic PAN promoter and can be quantitated.
When the expression of K-RBP was knocked down by siRNA
(Fig. 9B), the number of cells harboring reactivated KSHV was
higher upon induction by RTA compared to the number of
cells that were transfected with a control siRNA (Fig. 9C). Two
to three times more cells containing reactivated viruses were
consistently observed when KSHV lytic replication was in-
duced by expressing RTA in K-RBP knockdown cells (Fig.
9D). The enhancement was confirmed by measuring the amount
of viruses released in supernatant. The amount of viral DNA
was measured by PCR amplification of the ORF26 of KSHV
(Fig. 9E and F). Real-time PCR consistently detected a two-
fold-higher viral DNA level in medium of cells transfected with
K-RBP siRNA (Fig. 9F). In summary, these results suggest
that K-RBP can suppress KSHV lytic reactivation and that this
suppression may be in part mediated by the repression of
K-RBP in RTA-mediated transactivation of lytic gene expres-
sion.
DISCUSSION
It is estimated that there are more than 300 members of
KRAB-containing zinc finger proteins encoded in the human
genome (58), and some of them have been shown to function
as transcriptional repressors and play a role in gene silencing.
They have also been shown to have diverse functions, including
the maintenance of nucleus, cell differentiation, cell prolifera-
tion, apoptosis, and neoplastic transformation (13, 20, 24, 25,
71, 74, 83). These functions can be mediated directly or indi-
rectly by DNA binding activity of the zinc finger motifs within
these proteins or mediated by protein-protein interactions be-
tween KRAB-containing zinc finger proteins and other pro-
teins. TIF1 has been suggested to function as a molecule
targeted to promoter elements via its interaction with KRAB-
FIG. 7. TIF1 is involved in the downregulation of RTA-mediated transactivation of KSHV promoters. (A) 293T cells were transfected with
the reporter construct pK8Pluc (7.5 ng), a fixed amount (25 ng) of pCMV-Tag50, and increasing amounts (0, 250, 750 ng) of pHATIF1. Luciferase
activities were measured at 24 h after transfection. Luciferase reporter activities are expressed as a percentage of activation, with activation by RTA
alone equal to 100%. The error bars indicate standard deviations. (B) Transfection was carried out as described for panel A, except reporter
construct p57Pluc1 (20 ng) was used. (C) Transfection was carried out as described for panel A, except reporter construct pPANPluc (20 ng) was
used. (D) Western blot analysis for pCMV-Tag50 expression in transfected 293T cells in the presence or absence of pHATIF1. Lysates of cells
either transfected with pCMV-Tag50 alone or cotransfected with pHATIF1 expression plasmid were analyzed using anti-Flag, anti-HA, or
anti--tubulin antibodies. (E) 293T cells were transfected with the reporter construct pK8Pluc (7.5 ng), a fixed amount (25 ng) of pCMV-Tag50,
and indicated amounts of pHATIF1 or pcDNAK-RBP. Luciferase activities were measured at 24 h after transfection. Luciferase reporter
activities are expressed as a percentage of activation, with activation by RTA alone equal to 100%. The error bars indicate standard deviations.
(F) Transfection was carried out as described for panel E, except reporter construct p57Pluc1 (20 ng) was used. (G) Western blot analysis of
pCMV-Tag50 expression in transfected 293T cells in the presence of pHATIF1, pcDNAK-RBP, or both. Lysates of cells either transfected with
pCMV-Tag50 alone or cotransfected with pHATIF1, pcDNAK-RBP, or both expression plasmids were analyzed using anti-Flag, anti-HA,
anti-K-RBP, or anti--tubulin antibodies.
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containing zinc finger proteins. The HDAC-SETDB1 methyl-
ation complex and HP1 proteins are then recruited to the
promoter region and form a facultative heterochromatin envi-
ronment on the target promoter (63). TIF1 was shown to play
a crucial role in KRAB-mediated repression, and a mutant of
the KRAB domain of KRAB-containing zinc finger proteins
that cannot interact with TIF1 lost its repression function
(12). TIF1 interacts and synergizes with K-RBP to repress
RTA-mediated transactivation, suggesting that TIF1 serves
as a corepressor of K-RBP in similarity to the results seen with
other KRAB-containing zinc finger proteins. The stabilization
of K-RBP by TIF1 suggests that TIF1 not only functions as
a molecular scaffold for K-RBP to mediate repression but also
protects K-RBP from degradation to function as a transcrip-
tional repressor. Two other KRAB-containing proteins, c-Myc-
interacting Krim-1 and Krim-2, were also found to be stabilized by
TIF1 (20).
We could not rule out the possibility that K-RBP also reg-
ulates RTA transactivation through a KRAB domain-indepen-
dent mechanism, since there are several possible mechanisms
for K-RBP to regulate RTA function. First, K-RBP may bind
directly to DNA elements in the KSHV promoters to mediate
repression. This is consistent with the notion that zinc finger
motifs are DNA binding modules, and several KRAB-contain-
ing zinc finger proteins were found to have site-specific DNA
binding activity. We are currently in the process of carrying out
experiments to examine the potential DNA binding activity of
K-RBP and to determine whether such binding is necessary for
the regulation of RTA-mediated transactivation. Second, K-
RBP may function as a competitive inhibitor of RTA either
through direct interaction with RTA or by inhibiting the bind-
ing of RTA to its response elements. Third, K-RBP may func-
FIG. 9. K-RBP represses RTA-mediated KSHV lytic replication.
(A) TRExBCBL-1RTA cells were transfected either with pcDNA3.1
(lane 1) or with pcDNAK-RBP (lane 2). At 24 h posttransfection, cells
were treated with 1g/ml doxycycline to induce lytic replication of KSHV.
At 6 h (His-tagged RTA, RTA, and K8) and 24 h (K8.1 and LANA)
posttreatment, cells were harvested, lysed, and separated by SDS-PAGE,
and Western blot analysis was performed using antibodies as indicated.
Numbers indicate the relative amounts of K8, K8.1, and LANA proteins.
(B) Vero cells harboring rKSHV.219 were transfected with control or
K-RBP siRNA to knock down K-RBP expression, and K-RBP protein
was analyzed by Western blotting using anti-K-RBP antibody. (C) KSHV-
infected cells were infected by baculovirus expressing KSHV-RTA to
induce KSHV lytic replication. At 72 h after infection, latently infected
cells were detected by GFP expression and cells with lytic KSHV repli-
cation were detected by RFP expression. The cells with latent and lytic
KSHV replication were observed under microscopy. (D) The numbers of
cells expressing RFP as described for panel C were compared between
control and K-RBP siRNA-treated cells. The number of RFP-positive
cells in control siRNA-treated cells was normalized to 1. (E) KSHV-
infected cells were infected by baculovirus expressing KSHV-RTA to
induce KSHV lytic replication. At 96 h after infection, supernatants of
transfected cells were harvested and enriched for PCR amplification of
KSHV ORF26 to detect the virion production level of KSHV. (F) The
relative amounts of KSHV DNA were measured by real-time PCR, with
the DNA amount of control siRNA-transfected cells normalized to 1. The
error bars indicate standard deviations of the results obtained with three
PCR experiments.
FIG. 8. Knockdown of K-RBP and TIF1 enhances RTA-medi-
ated transactivation of the ORF57 promoter. (A) 293T cells were
transfected with indicated siRNA. The total amount of siRNA in each
well was normalized by use of the control siRNA. At 24 h after siRNA
transfection, the reporter construct p57Pluc1 (20 ng) and RTA expres-
sion plasmid pCMV-Tag50 (25 ng) were transfected into the cells.
Luciferase activities were measured at 24 h after transfection. Lucif-
erase reporter activities were expressed as a percentage of activation,
with activation by RTA with control siRNA made equal to 100%. The
error bars indicate standard deviations. (B) Western blot analysis of
the expression of RTA, TIF1, K-RBP, and tubulin in cells transfected
using different siRNAs, identical amounts of pCMV-Tag50, and indi-
cated antibodies.
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tion as a repressor of RTA similarly to HDAC, which was
found to interact with RTA to repress RTA-mediated trans-
activation (17). It is possible that other cellular factors such as
TIF1 recruited by K-RBP are also involved. The presence of
TIF1 in the promoter region may then suppress RTA-medi-
ated transactivation through the formation of heterochroma-
tin. TIF1 could enhance the repression by functioning as a
corepressor in the RTA/K-RBP complex or increase the sta-
bility of K-RBP. Further experiments are required to decipher
whether one or more of these mechanisms are involved.
RTA is an important immediate-early viral protein that in-
duces KSHV lytic replication. It can activate numerous KSHV
genes, including ORF57, PAN RNA, K8, TK, LANA, and
itself (6, 10, 11, 29, 46, 54, 68, 69). It has been suggested that
RTA can bind to elements located in the target promoters
either directly or indirectly to activate transcription (41, 68).
The indirect binding involves several cellular factors. For ex-
ample, RBP-J was demonstrated to play a critical role in RTA
binding to its response element in the ORF57 promoter (32,
33). Several other cellular factors such as C/EBP, CBP/p300,
and the SWI/SNF complex were found to enhance RTA trans-
activation and viral replication (16, 17, 81). KSHV infection
has been shown to lead to initial lytic replication and limited
viral production, but this is quickly followed by a shutoff of
viral replication leading to latency (27), suggesting that RTA
activity is downregulated in this process. In addition, KSHV is
latent in many KSHV-infected cells, suggesting that RTA ex-
pression and function are tightly controlled in these cells. The
downregulation of RTA is likely to involve a number of viral
and cellular factors, and the viral LANA and KbZIP proteins
were shown to be involved in shutting down RTA lytic viral
replication (22, 28, 35). In addition, a number of cellular fac-
tors were found to downregulate RTA transactivation. They
include HDAC, IRF-7, PARP-1, hKFC, and NF-B (5, 17, 19,
78). They either posttranslationally modify RTA protein or
interfere with RTA binding to its response elements in the viral
promoters to suppress the RTA-mediated transactivation. K-
RBP, as reported in this paper, is another cellular factor that
can regulate RTA transactivation. The effect of K-RBP on
RTA transactivation appears to be dose dependent. In trans-
fection assays, we have previously shown that K-RBP activated
RTA-mediated transactivation (80). This was substantiated
when K-RBP was expressed at low concentrations. However,
with an increasing amount of K-RBP, as reported here, it acts
as a repressor of transcription, in similarity to what was ob-
served with other KRAB-containing zinc finger proteins. The
various effects of K-RBP on RTA could be due to the effect of
RTA and K-RBP on the expression of a number of cellular
genes that can either up- or downregulate the interplay be-
tween RTA and K-RBP or could be due to different cellular
factors present in the promoter regions with various amounts
of K-RBP protein. These effects may lead to feedback regula-
tion that is usually highly dosage dependent. In addition, K-
RBP may play different roles in different stages of KSHV
reactivation and de novo infection and in different cell types
when the expression levels of RTA and K-RBP vary. Since
RTA is known to complex with a number of viral and cellular
proteins, including K-RBP, it is likely that the modulation of
RTA function by these cellular and viral factors contributes to
the regulation of KSHV lytic replication. Further studies of
how these factors and RTA interact may lead to new strategies
to control the switch of KSHV to lytic replication from latency.
In our study, overexpression of K-RBP in TRExBCBL-
1RTA cells suppressed KSHV lytic replication. This suggests
that K-RBP could be the negative regulator in RTA-mediated
KSHV reactivation. This was confirmed by K-RBP knockdown
experiments using Vero cells latently infected by KSHV. The
knockdown of K-RBP can enhance lytic viral reactivation.
However, even though the effect of K-RBP on KSHV lytic
replication is consistent, neither the overexpression of K-RBP
nor its knockdown led to a dramatic effect on KSHV lytic
replication. Overexpression of K-RBP led to a 30 to 50%
reduction of expression of lytic proteins K8 and K8.1. Similarly,
K-RBP knockdown led to a two- to threefold increase in lytic
replication upon RTA induction. This is likely due to the
involvement of a number of other viral and cellular proteins in
the RTA-mediated regulation of lytic replication, and K-RBP
is only one of a number of cellular factors involved. Many of
them may have overlapping functions, so the overexpression or
elimination of one, such as K-RBP, would not have an over-
whelming effect on KSHV lytic replication. In addition, K-RBP
could not be completely knocked out by siRNA with a low level
of K-RBP still being expressed and may have an effect on viral
replication. Moreover, the knockdown study was not carried
out using B cells, since K-RBP could not be knocked down
efficiently in the various B-cell lines that were tested. At this
point, we cannot rule out the possibility that K-RBP affects
KSHV reactivation indirectly through an RTA-independent
pathway, but it is likely that the suppression of RTA by K-RBP
contributes to the suppression of KSHV reactivation and the
establishment of KSHV latency.
K-RBP is ubiquitously expressed in different cell lines and
tissues (66, 80), but little is known about the normal function
of this protein and its role in the regulation of RTA function.
Our study thus demonstrated that this KRAB-containing zinc
finger protein could function as a transcriptional repressor and
that it is involved in the regulation of KSHV transcriptional
activator RTA and in KSHV gene expression and reactivation.
This study not only added a new member to the KRAB-con-
taining zinc finger protein family experimentally but also added
a novel function to this protein family, namely, its involvement
in the regulation of KSHV viral gene expression, and has
provided new insights with respect to studying the regulation of
KSHV latency and lytic replication.
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